Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 126

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 126
---
pipeline
product” of the Company is designated as GelrinP and it is a product using a conjugate of fibrinogen with a polaxamer (Pluronic)
for the treatment of osteoarthritis. The product exhibits thermo-reversible gelation, is water-immiscible and can be delivered using
a minimally invasive application. It is designed to a form of a paste in the cavity upon UVA irradiation.

This product is more viscous
and better suited for the intended purpose of providing relief from chronic conditions including osteoarthritis. This second potential
product is described by the third family of patents derived from WO 2011/07399, which was filed December 16, 2010. Patents from this
family are nominally due to expire in December 2030 and include patents Nos. US 8,846,020, EP 2513294, CN 102762715 and IL 220343, which
are detailed in the table below.

Family #2 derived from WO 2008/126092
that was filed April 16, 2008 claims conjugates of the serum protein albumin with PEG. This patent may be useful to supplement the protection
of GelrinC which may contain albumin as well as fibrinogen. The family of patent applications derived from WO 2008/126092 includes patents
Nos. US 9,624,259 and EP 2497505, which are detailed in the table below.

Family 

# 4 derived from WO 2014/207749
filed June 24, 2014 claims an injectable curable paste that can be shaped to fill defects requiring treatment. The family of patent applications
derived from WO 2014/207749 includes patents Nos. US 10,434,215, EP 3013377 and CN 105407933, which are detailed in the table below.

Family #6 derived from WO 2015/052708
filed on January 24, 2014 claim an apparatus for treatment of cavities in a human body. The family of patent applications derived from
WO 2015/052708 includes patents Nos. US 9,895,519, US 9,872,705, EP 2874546, CN 106232023 and IL 235270, which are detailed in the table
below.

The patent portfolio of the
Company includes granted patents that cover the